Literature DB >> 15854176

Managing dyspepsia without alarm signs in primary care: new national guidance for England and Wales.

J M Mason1, B Delaney, P Moayyedi, M Thomas, R Walt.   

Abstract

AIM: To report new recommendations for the primary care management of dyspepsia without alarm signs in England and Wales.
METHOD: An independent, representative group of health care professionals, patient representatives and researchers developed the guideline using evidence-based and small group-working principles, and incorporated extensive peer-reviewing and feedback from stakeholder organizations.
RESULTS: Referral to investigate dyspepsia should be made for alarm signs and not on the basis of age alone, reflecting the balance of benefit and harm from endoscopy. Empirical management without formal diagnosis is appropriate for most patients: reviewing patient history, lifestyle, over-the-counter medicines, and providing a course of proton-pump inhibitors and/or Helicobacter pylori test and treatment. Patients with ongoing symptoms require at least annual review to discuss symptoms and lifestyle, and as appropriate, encourage stepping down prescribed medication and returning to self-care. A new strategy included in the step down process is the use of therapies 'on-demand'.
CONCLUSION: The guideline provides structured and supported recommendations for both undiagnosed and endoscopically investigated dyspepsia. Some favour increased investigation to detect Barrett's oesophagus and carcinoma. However, there is inconclusive evidence that patients without alarm signs will benefit subsequently from endoscopy, while investigation involves a small but real risk of harm.

Entities:  

Mesh:

Year:  2005        PMID: 15854176     DOI: 10.1111/j.1365-2036.2005.02445.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Who benefits from Helicobacter pylori eradication?

Authors:  Brendan C Delaney
Journal:  BMJ       Date:  2006-01-28

2.  Biodegradable stent or balloon dilatation for benign oesophageal stricture: pilot randomised controlled trial.

Authors:  Anjan Dhar; Helen Close; Yirupaiahgari K Viswanath; Colin J Rees; Helen C Hancock; A Deepak Dwarakanath; Rebecca H Maier; Douglas Wilson; James M Mason
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

3.  Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study.

Authors:  Yoshikazu Kinoshita; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2011-12-21       Impact factor: 7.527

Review 4.  Role of Helicobacter pylori in functional dyspepsia.

Authors:  Colm O'Morain
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

5.  Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial).

Authors:  Brendan C Delaney; Michelle Qume; Paul Moayyedi; Richard F A Logan; Alexander C Ford; Cathy Elliott; Cliodna McNulty; Sue Wilson; F D Richard Hobbs
Journal:  BMJ       Date:  2008-02-29

6.  A Simple Pre-endoscopy Score for Predicting Risk of Malignancy in Patients with Dyspepsia: A 5-Year Prospective Study.

Authors:  Amit Kumar Dutta; Grace Rebekah; Sudipta Dhar Chowdhury; Sajith Kattiparambil Gangadharan; Yuvaraj Subramani; Manoj Kumar Sahu; Reuben Thomas Kurien; Deepu David; Ebby George Simon; Anjilivelil Joseph Joseph; Viswanath Reddy Donapati; Ashok Chacko
Journal:  Dig Dis Sci       Date:  2018-08-14       Impact factor: 3.199

7.  Proton pump inhibitors: potential cost reductions by applying prescribing guidelines.

Authors:  Caitriona Cahir; Tom Fahey; Lesley Tilson; Conor Teljeur; Kathleen Bennett
Journal:  BMC Health Serv Res       Date:  2012-11-19       Impact factor: 2.655

8.  Effect of licorice versus bismuth on eradication of Helicobacter pylori in patients with peptic ulcer disease.

Authors:  Ali Momeni; Ghorbanali Rahimian; Abass Kiasi; Masoud Amiri; Soleiman Kheiri
Journal:  Pharmacognosy Res       Date:  2014-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.